Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis

Ann Med. 2024 Dec;56(1):2357235. doi: 10.1080/07853890.2024.2357235. Epub 2024 May 30.

Abstract

Objective: Tension-type headache is the most common type of primary headache and results in a huge socioeconomic burden. This network meta-analysis (NMA) aimed to compare the efficacy and safety of simple analgesics for the treatment of episodic tension-type headache (ETTH) in adults.

Methods: We searched the Cochrane Library, PubMed, Web of Science, Embase, Chinese BioMedical Literature database and International Clinical Trials Registry Platform databases for eligible randomized clinical trials reporting the efficacy and/or safety of simple analgesics. A Bayesian NMA was performed to compare relative efficacy and safety. The surface under the cumulative ranking curve (SUCRA) was calculated to rank interventions. PROSPERO registration number: CRD42018090554.

Results: We highlighted six studies including 3507 patients. For the 2 h pain-free rate, the SUCRA ranking was ibuprofen > diclofenac-K > ketoprofen > acetaminophen > naproxen > placebo. All drugs except naproxen reported a higher 2 h pain-free rate than placebo, with a risk ratio (RR) of 2.86 (95% credible interval, CrI: 1.62-5.42) for ibuprofen and 2.61 (1.53-4.88) for diclofenac-K. For adverse events rate, the SUCRA ranking was: metamizol > diclofenac-K > ibuprofen > lumiracoxib > placebo > aspirin > acetaminophen > naproxen > ketoprofen. The adverse event rates of all analgesics were no higher than those of placebo, except for ketoprofen. Moreover, all drugs were superior to placebo in the global assessment of efficacy. In particular, the RR of lumiracoxib was 2.47 (1.57-4.57). Global heterogeneity I2 between the studies was low.

Conclusions: Simple analgesics are considered more effective and safe as a placebo for ETTH in adults. Our results suggest that ibuprofen and diclofenac-K may be the two best treatment options for patients with ETTH from a comprehensive point of view (both high-quality evidence).

Keywords: Tension-type headache; efficacy; network meta-analysis; safety; simple analgesics.

Plain language summary

To our knowledge, this is the first network meta-analysis comparing the available data on adult patients with episodic tension-type headache (ETTH) treated with different simple analgesics recommended by the current guidelines.Ibuprofen (400 mg) and diclofenac-K (12.5 mg, 25 mg) are potentially the most effective and safe treatment options, supported by high-quality evidence.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Acetaminophen / administration & dosage
  • Acetaminophen / adverse effects
  • Acetaminophen / therapeutic use
  • Adult
  • Analgesics* / administration & dosage
  • Analgesics* / adverse effects
  • Analgesics* / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Bayes Theorem
  • Diclofenac / administration & dosage
  • Diclofenac / adverse effects
  • Diclofenac / therapeutic use
  • Female
  • Humans
  • Ibuprofen* / administration & dosage
  • Ibuprofen* / adverse effects
  • Ibuprofen* / therapeutic use
  • Ketoprofen / administration & dosage
  • Ketoprofen / adverse effects
  • Ketoprofen / analogs & derivatives
  • Ketoprofen / therapeutic use
  • Male
  • Naproxen / administration & dosage
  • Naproxen / adverse effects
  • Naproxen / therapeutic use
  • Network Meta-Analysis*
  • Randomized Controlled Trials as Topic
  • Tension-Type Headache* / drug therapy
  • Treatment Outcome

Substances

  • Analgesics
  • Ibuprofen
  • Acetaminophen
  • Diclofenac
  • Naproxen
  • Ketoprofen
  • Anti-Inflammatory Agents, Non-Steroidal

Grants and funding

This research was supported by the National Natural Science Foundation of China (72204061), Guangdong Medical Science and Technology Research Fund Project (B2021466), Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (YN2023QN05, YN2020QN17), Science and Technology Planning Project of Guangdong Province (2021B1212100007) and Guangzhou Science and Technology Plan Project (2023B03J1226).